Cargando…

Untreated PKU Patients without Intellectual Disability: What Do They Teach Us?

Phenylketonuria (PKU) management is aimed at preventing neurocognitive and psychosocial dysfunction by keeping plasma phenylalanine concentrations within the recommended target range. It can be questioned, however, whether universal plasma phenylalanine target levels would result in optimal neurocog...

Descripción completa

Detalles Bibliográficos
Autores principales: van Vliet, Danique, van Wegberg, Annemiek M.J., Ahring, Kirsten, Bik-Multanowski, Miroslaw, Casas, Kari, Didycz, Bozena, Djordjevic, Maja, Hertecant, Jozef L., Leuzzi, Vincenzo, Mathisen, Per, Nardecchia, Francesca, Powell, Kimberly K., Rutsch, Frank, Stojiljkovic, Maja, Trefz, Fritz K., Usurelu, Natalia, Wilson, Callum, van Karnebeek, Clara D., Hanley, William B., van Spronsen, Francjan J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6893397/
https://www.ncbi.nlm.nih.gov/pubmed/31731404
http://dx.doi.org/10.3390/nu11112572
_version_ 1783476189185179648
author van Vliet, Danique
van Wegberg, Annemiek M.J.
Ahring, Kirsten
Bik-Multanowski, Miroslaw
Casas, Kari
Didycz, Bozena
Djordjevic, Maja
Hertecant, Jozef L.
Leuzzi, Vincenzo
Mathisen, Per
Nardecchia, Francesca
Powell, Kimberly K.
Rutsch, Frank
Stojiljkovic, Maja
Trefz, Fritz K.
Usurelu, Natalia
Wilson, Callum
van Karnebeek, Clara D.
Hanley, William B.
van Spronsen, Francjan J.
author_facet van Vliet, Danique
van Wegberg, Annemiek M.J.
Ahring, Kirsten
Bik-Multanowski, Miroslaw
Casas, Kari
Didycz, Bozena
Djordjevic, Maja
Hertecant, Jozef L.
Leuzzi, Vincenzo
Mathisen, Per
Nardecchia, Francesca
Powell, Kimberly K.
Rutsch, Frank
Stojiljkovic, Maja
Trefz, Fritz K.
Usurelu, Natalia
Wilson, Callum
van Karnebeek, Clara D.
Hanley, William B.
van Spronsen, Francjan J.
author_sort van Vliet, Danique
collection PubMed
description Phenylketonuria (PKU) management is aimed at preventing neurocognitive and psychosocial dysfunction by keeping plasma phenylalanine concentrations within the recommended target range. It can be questioned, however, whether universal plasma phenylalanine target levels would result in optimal neurocognitive outcomes for all patients, as similar plasma phenylalanine concentrations do not seem to have the same consequences to the brain for each PKU individual. To better understand the inter-individual differences in brain vulnerability to high plasma phenylalanine concentrations, we aimed to identify untreated and/or late-diagnosed PKU patients with near-normal outcome, despite high plasma phenylalanine concentrations, who are still alive. In total, we identified 16 such cases. While intellectual functioning in these patients was relatively unaffected, they often did present other neurological, psychological, and behavioral problems. Thereby, these “unusual” PKU patients show that the classical symptomatology of untreated or late-treated PKU may have to be rewritten. Moreover, these cases show that a lack of intellectual dysfunction despite high plasma phenylalanine concentrations does not necessarily imply that these high phenylalanine concentrations have not been toxic to the brain. Also, these cases may suggest that different mechanisms are involved in PKU pathophysiology, of which the relative importance seems to differ between patients and possibly also with increasing age. Further research should aim to better distinguish PKU patients with respect to their cerebral effects to high plasma phenylalanine concentrations.
format Online
Article
Text
id pubmed-6893397
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-68933972019-12-23 Untreated PKU Patients without Intellectual Disability: What Do They Teach Us? van Vliet, Danique van Wegberg, Annemiek M.J. Ahring, Kirsten Bik-Multanowski, Miroslaw Casas, Kari Didycz, Bozena Djordjevic, Maja Hertecant, Jozef L. Leuzzi, Vincenzo Mathisen, Per Nardecchia, Francesca Powell, Kimberly K. Rutsch, Frank Stojiljkovic, Maja Trefz, Fritz K. Usurelu, Natalia Wilson, Callum van Karnebeek, Clara D. Hanley, William B. van Spronsen, Francjan J. Nutrients Article Phenylketonuria (PKU) management is aimed at preventing neurocognitive and psychosocial dysfunction by keeping plasma phenylalanine concentrations within the recommended target range. It can be questioned, however, whether universal plasma phenylalanine target levels would result in optimal neurocognitive outcomes for all patients, as similar plasma phenylalanine concentrations do not seem to have the same consequences to the brain for each PKU individual. To better understand the inter-individual differences in brain vulnerability to high plasma phenylalanine concentrations, we aimed to identify untreated and/or late-diagnosed PKU patients with near-normal outcome, despite high plasma phenylalanine concentrations, who are still alive. In total, we identified 16 such cases. While intellectual functioning in these patients was relatively unaffected, they often did present other neurological, psychological, and behavioral problems. Thereby, these “unusual” PKU patients show that the classical symptomatology of untreated or late-treated PKU may have to be rewritten. Moreover, these cases show that a lack of intellectual dysfunction despite high plasma phenylalanine concentrations does not necessarily imply that these high phenylalanine concentrations have not been toxic to the brain. Also, these cases may suggest that different mechanisms are involved in PKU pathophysiology, of which the relative importance seems to differ between patients and possibly also with increasing age. Further research should aim to better distinguish PKU patients with respect to their cerebral effects to high plasma phenylalanine concentrations. MDPI 2019-10-25 /pmc/articles/PMC6893397/ /pubmed/31731404 http://dx.doi.org/10.3390/nu11112572 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
van Vliet, Danique
van Wegberg, Annemiek M.J.
Ahring, Kirsten
Bik-Multanowski, Miroslaw
Casas, Kari
Didycz, Bozena
Djordjevic, Maja
Hertecant, Jozef L.
Leuzzi, Vincenzo
Mathisen, Per
Nardecchia, Francesca
Powell, Kimberly K.
Rutsch, Frank
Stojiljkovic, Maja
Trefz, Fritz K.
Usurelu, Natalia
Wilson, Callum
van Karnebeek, Clara D.
Hanley, William B.
van Spronsen, Francjan J.
Untreated PKU Patients without Intellectual Disability: What Do They Teach Us?
title Untreated PKU Patients without Intellectual Disability: What Do They Teach Us?
title_full Untreated PKU Patients without Intellectual Disability: What Do They Teach Us?
title_fullStr Untreated PKU Patients without Intellectual Disability: What Do They Teach Us?
title_full_unstemmed Untreated PKU Patients without Intellectual Disability: What Do They Teach Us?
title_short Untreated PKU Patients without Intellectual Disability: What Do They Teach Us?
title_sort untreated pku patients without intellectual disability: what do they teach us?
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6893397/
https://www.ncbi.nlm.nih.gov/pubmed/31731404
http://dx.doi.org/10.3390/nu11112572
work_keys_str_mv AT vanvlietdanique untreatedpkupatientswithoutintellectualdisabilitywhatdotheyteachus
AT vanwegbergannemiekmj untreatedpkupatientswithoutintellectualdisabilitywhatdotheyteachus
AT ahringkirsten untreatedpkupatientswithoutintellectualdisabilitywhatdotheyteachus
AT bikmultanowskimiroslaw untreatedpkupatientswithoutintellectualdisabilitywhatdotheyteachus
AT casaskari untreatedpkupatientswithoutintellectualdisabilitywhatdotheyteachus
AT didyczbozena untreatedpkupatientswithoutintellectualdisabilitywhatdotheyteachus
AT djordjevicmaja untreatedpkupatientswithoutintellectualdisabilitywhatdotheyteachus
AT hertecantjozefl untreatedpkupatientswithoutintellectualdisabilitywhatdotheyteachus
AT leuzzivincenzo untreatedpkupatientswithoutintellectualdisabilitywhatdotheyteachus
AT mathisenper untreatedpkupatientswithoutintellectualdisabilitywhatdotheyteachus
AT nardecchiafrancesca untreatedpkupatientswithoutintellectualdisabilitywhatdotheyteachus
AT powellkimberlyk untreatedpkupatientswithoutintellectualdisabilitywhatdotheyteachus
AT rutschfrank untreatedpkupatientswithoutintellectualdisabilitywhatdotheyteachus
AT stojiljkovicmaja untreatedpkupatientswithoutintellectualdisabilitywhatdotheyteachus
AT trefzfritzk untreatedpkupatientswithoutintellectualdisabilitywhatdotheyteachus
AT usurelunatalia untreatedpkupatientswithoutintellectualdisabilitywhatdotheyteachus
AT wilsoncallum untreatedpkupatientswithoutintellectualdisabilitywhatdotheyteachus
AT vankarnebeekclarad untreatedpkupatientswithoutintellectualdisabilitywhatdotheyteachus
AT hanleywilliamb untreatedpkupatientswithoutintellectualdisabilitywhatdotheyteachus
AT vanspronsenfrancjanj untreatedpkupatientswithoutintellectualdisabilitywhatdotheyteachus